Harold H. Shlevin, serving as a director at Galectin Therapeutics Inc. (NASDAQ: GALT), has finalized a series of stock transactions involving the company's common equity. SEC Form 4 filings detail the disposal of 30,000 shares, generating aggregate proceeds of roughly $150,890. These sales were facilitated under a Rule 10b5-1 trading plan, a mechanism designed to allow executives to transact shares while adhering to regulatory compliance standards. The execution of these sales occurred against a backdrop of significant price appreciation for GALT shares, which surged nearly 49% over the preceding week. Despite this momentum, current valuation metrics from InvestingPro suggest the stock is trading above its calculated Fair Value and currently occupies a position on the platform's Most Overvalued list.
The transaction timeline spans late June 2026. On June 26, Shlevin disposed of 7,732 shares at a weighted average price of $5.00 per share. Three days later, on June 29, he sold an additional 22,268 shares at a weighted average price of $5.04 per share. The total value derived from these specific sales events amounted to approximately $150,890. Prior to executing these sales, Shlevin acquired the exact same quantity of 30,000 shares through the exercise of stock options. These options, which vested 100% on December 31, 2025, carried an exercise price of $1.23 per share, resulting in a total acquisition cost of approximately $36,900. Following the completion of these reported transactions, Shlevin's direct holding in Galectin Therapeutics common stock stands at 6,500 shares.
Concurrent with the insider activity, Galectin Therapeutics has reported substantial progress in its clinical development pipeline for belapectin. The company announced a formal agreement with the U.S. Food and Drug Administration (FDA) regarding the design of a Phase 3 trial for belapectin, a therapeutic candidate targeting patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. This regulatory alignment follows a Type C meeting with the FDA and establishes the study design, primary endpoint, and regulatory framework for the upcoming trial. Additionally, the company published results from its NAVIGATE Phase 2b clinical trial in the journal Hepatology. This global, randomized, placebo-controlled study, conducted over an 18-month period, evaluated belapectin in patients with MASH cirrhosis and portal hypertension without baseline esophageal varices. These milestones highlight the company's advancing clinical efforts and regulatory engagement.